Brain Infection Herpes Test Gets FDA Safety Nod
Published Date: 6/26/2025
Rule
Summary
The FDA is officially putting the herpes simplex virus test for brain infections into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get better access to this important tool. The change aims to make things smoother for companies without costing extra time or money.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Test Classified as Class II Device
The FDA has officially classified the herpes simplex virus nucleic acid-based assay for central nervous system infections as a Class II device with special controls. This means the FDA says there are special rules to help ensure the test is safe and effective.
Rule Aims to Improve Patient Access
The FDA says this Class II classification will enhance patients' access to beneficial innovative devices by reducing regulatory burdens. That means the FDA expects the change to help get this kind of herpes simplex virus test to patients more easily.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in